Tumor Mutational Burden
EstablishedTMB is a tissue-agnostic predictive biomarker for checkpoint inhibitor response, though weaker and more debated than PD-L1 or MSI-H.
TMB counts how many mutations a tumor has picked up. Cancers with lots of mutations sometimes look more "foreign" to the immune system, making immunotherapy more likely to work. But this marker is a weaker predictor than some others, and only one specific lab test currently carries formal FDA backing for this use.
Tumor mutational burden (TMB) quantifies the total number of mutations per megabase of tumor DNA; it is one of three FDA-approved predictive biomarkers for immune checkpoint inhibitor response, reflecting the idea that more mutations generally means more neoantigens for the immune system to potentially recognize.
High TMB (≥10 mutations/megabase using the FDA-approved cutoff) supports pembrolizumab use as a tissue-agnostic indication in advanced solid tumors that have progressed after prior treatment and lack other options.
Measured via large next-generation sequencing (NGS) gene panels; the FoundationOne CDx assay is currently the only FDA-approved test for this specific indication, meaning results from other sequencing panels, even if accurate, don't carry the same formal regulatory backing for this use.
TMB-high status alone is a weaker predictor of checkpoint inhibitor benefit than PD-L1 or MSI-H in some analyses, and its clinical utility remains genuinely debated in the oncology community; it's generally considered a second-line consideration when other markers are unavailable or uninformative.
Only one specific NGS panel (FoundationOne CDx) carries FDA approval for this particular clinical use.
- PMC. (2023). Predictive biomarkers of response to immune checkpoint inhibitors in immuno-oncology.